@article{e5648409e0a9440fb85eb6a10850db61,
title = "Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults with Overweight or Obesity - Reply",
author = "Ildiko Lingvay and Garvey, {W. Timothy} and Wadden, {Thomas A.}",
note = "Funding Information: the National Institutes of Health (NIH) (National Institute on Aging [NIA]). Dr Glymour reported receiving grants from the NIH (NIA, National Institute on Minority Health and Health Disparities, Eunice Kennedy Shriver National Institute of Child Health and Human Development, and National Institute on Alcohol Abuse and Alcoholism) and the Robert Wood Johnson Evidence for Action Program. Funding Information: Conflict of Interest Disclosures: Dr Lingvay reported receipt of grants from Novo Nordisk, Merck, Pfizer, Mylan, and Sanofi; personal fees from Novo Nordisk, Lilly, Sanofi, Merck, AstraZeneca, Janssen, Boehringer Ingelheim, Bayer, Target Pharma, Zealand Pharma, and Intercept; and nonfinancial support from Novo Nordisk, Merck, Boehringer Ingelheim, AstraZeneca, Janssen, Lilly, and Sanofi. Dr Garvey reported serving as site principal investigator for clinical trials sponsored by the University of Alabama at Birmingham that were funded by Novo Nordisk, Pfizer, Eli Lilly, and Epitomee. Dr Wadden reported receipt of personal fees from Novo Nordisk and serving on a scientific advisory board for Novo Nordisk.",
year = "2021",
month = sep,
day = "28",
doi = "10.1001/jama.2021.13024",
language = "English (US)",
volume = "326",
pages = "1214--1215",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "12",
}